drug

trastuzumab-anns

1 story · latest Nov 2, 2026

Follow trastuzumab-anns. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: FDA approved Jun 2019 · BLA761073
Brand: Kanjinti

Relationships

Developed by Amgen

Timeline

Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%

Nov 2Quarterly updateAmgen Aprea Therapeutics

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.